Literature DB >> 30232278

Long-term remission despite clonal expansion of replication-competent HIV-1 isolates.

Rebecca T Veenhuis1,2, Abena K Kwaa1, Caroline C Garliss1, Rachel Latanich1, Maria Salgado1, Christopher W Pohlmeyer1, Christopher L Nobles3, John Gregg3, Eileen P Scully1, Justin R Bailey1, Frederic D Bushman3, Joel N Blankson1,2.   

Abstract

Clonal expansion of T cells harboring replication-competent virus has recently been demonstrated in patients on suppressive antiretroviral therapy (ART) regimens. However, there has not been direct evidence of this phenomenon in settings of natural control, including in posttreatment controllers who maintain control of viral replication after treatment when ART is discontinued. We present a case of an individual who has had undetectable viral loads for more than 15 years following the cessation of ART. Using near-full-genome sequence analysis, we demonstrate that 9 of 12 replication-competent isolates cultured from this subject were identical and that this identity was maintained 6 months later. A similar pattern of replication-competent virus clonality was seen in a treatment-naive HLA-B*57 elite controller. In both cases, we show that CD8+ T cells are capable of suppressing the replication of the clonally expanded viruses in vitro. Our data suggest that, while clonal expansion of replication-competent virus can present a barrier to viral eradication, these viral isolates remain susceptible to HIV-specific immune responses and can be controlled in patients with long-term suppression of viral replication.

Entities:  

Keywords:  AIDS vaccine; AIDS/HIV; T cells

Mesh:

Substances:

Year:  2018        PMID: 30232278      PMCID: PMC6237238          DOI: 10.1172/jci.insight.122795

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  48 in total

1.  Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus.

Authors:  Karen A O'Connell; Timothy P Brennan; Justin R Bailey; Stuart C Ray; Robert F Siliciano; Joel N Blankson
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

Review 2.  Post-Treatment Controllers: Role in HIV "Cure" Research.

Authors:  Leslie R Cockerham; Hiroyu Hatano; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

3.  Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells.

Authors:  Guinevere Q Lee; Nina Orlova-Fink; Kevin Einkauf; Fatema Z Chowdhury; Xiaoming Sun; Sean Harrington; Hsiao-Hsuan Kuo; Stephane Hua; Hsiao-Rong Chen; Zhengyu Ouyang; Kavidha Reddy; Krista Dong; Thumbi Ndung'u; Bruce D Walker; Eric S Rosenberg; Xu G Yu; Mathias Lichterfeld
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

4.  The neighbor-joining method: a new method for reconstructing phylogenetic trees.

Authors:  N Saitou; M Nei
Journal:  Mol Biol Evol       Date:  1987-07       Impact factor: 16.240

5.  HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

Authors:  K L Collins; B K Chen; S A Kalams; B D Walker; D Baltimore
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

6.  Effective downregulation of HLA-A*2 and HLA-B*57 by primary human immunodeficiency virus type 1 isolates cultured from elite suppressors.

Authors:  Eric Nou; Yan Zhou; Damaris D Nou; Joel N Blankson
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

7.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.

Authors:  Michael R Betts; Martha C Nason; Sadie M West; Stephen C De Rosa; Stephen A Migueles; Jonathan Abraham; Michael M Lederman; Jose M Benito; Paul A Goepfert; Mark Connors; Mario Roederer; Richard A Koup
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113

8.  Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations.

Authors:  Kai Deng; Mihaela Pertea; Anthony Rongvaux; Leyao Wang; Christine M Durand; Gabriel Ghiaur; Jun Lai; Holly L McHugh; Haiping Hao; Hao Zhang; Joseph B Margolick; Cagan Gurer; Andrew J Murphy; David M Valenzuela; George D Yancopoulos; Steven G Deeks; Till Strowig; Priti Kumar; Janet D Siliciano; Steven L Salzberg; Richard A Flavell; Liang Shan; Robert F Siliciano
Journal:  Nature       Date:  2015-01-07       Impact factor: 49.962

Review 9.  Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic Controllers.

Authors:  Elena Gonzalo-Gil; Uchenna Ikediobi; Richard E Sutton
Journal:  Yale J Biol Med       Date:  2017-06-23

10.  INSPIIRED: A Pipeline for Quantitative Analysis of Sites of New DNA Integration in Cellular Genomes.

Authors:  Eric Sherman; Christopher Nobles; Charles C Berry; Emmanuelle Six; Yinghua Wu; Anatoly Dryga; Nirav Malani; Frances Male; Shantan Reddy; Aubrey Bailey; Kyle Bittinger; John K Everett; Laure Caccavelli; Mary J Drake; Paul Bates; Salima Hacein-Bey-Abina; Marina Cavazzana; Frederic D Bushman
Journal:  Mol Ther Methods Clin Dev       Date:  2016-12-18       Impact factor: 6.698

View more
  21 in total

1.  Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8+ T Cells.

Authors:  Abena K R Kwaa; Chloe A G Talana; Joel N Blankson
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

2.  BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo.

Authors:  Yanqin Ren; Szu Han Huang; Shabnum Patel; Winiffer D Conce Alberto; Dean Magat; Dughan Ahimovic; Amanda B Macedo; Ryan Durga; Dora Chan; Elizabeth Zale; Talia M Mota; Ronald Truong; Thomas Rohwetter; Chase D McCann; Colin M Kovacs; Erika Benko; Avery Wimpelberg; Christopher Cannon; W David Hardy; Alberto Bosque; Catherine M Bollard; R Brad Jones
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

3.  Replacing cART with CAR-T Cells: Using Immunotherapy to Cure HIV.

Authors:  Sarah E Beck; Joel N Blankson
Journal:  Mol Ther       Date:  2020-06-20       Impact factor: 11.454

4.  Longitudinal study reveals HIV-1-infected CD4+ T cell dynamics during long-term antiretroviral therapy.

Authors:  Annukka Ar Antar; Katharine M Jenike; Sunyoung Jang; Danielle N Rigau; Daniel B Reeves; Rebecca Hoh; Melissa R Krone; Jeanne C Keruly; Richard D Moore; Joshua T Schiffer; Bareng As Nonyane; Frederick M Hecht; Steven G Deeks; Janet D Siliciano; Ya-Chi Ho; Robert F Siliciano
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

5.  Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2.

Authors:  Bezawit A Woldemeskel; Abena K Kwaa; Caroline C Garliss; Oliver Laeyendecker; Stuart C Ray; Joel N Blankson
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

6.  Nonsuppressible HIV-1 viremia: a reflection of how the reservoir persists.

Authors:  Janet D Siliciano; Robert F Siliciano
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

Review 7.  Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure.

Authors:  Janet D Siliciano; Robert F Siliciano
Journal:  J Infect Dis       Date:  2021-02-15       Impact factor: 5.226

8.  CD8 Effector T Cells Function Synergistically With Broadly Neutralizing Antibodies to Enhance Suppression of HIV Infection.

Authors:  Rebecca T Veenhuis; Caroline C Garliss; Justin R Bailey; Joel N Blankson
Journal:  Front Immunol       Date:  2021-07-29       Impact factor: 7.561

9.  Elite suppressors have low frequencies of intact HIV-1 proviral DNA.

Authors:  Abena Kr Kwaa; Caroline C Garliss; Kristen D Ritter; Gregory M Laird; Joel N Blankson
Journal:  AIDS       Date:  2020-03-15       Impact factor: 4.632

Review 10.  Immunological effector mechanisms in HIV-1 elite controllers.

Authors:  Ciputra Adijaya Hartana; Xu G Yu
Journal:  Curr Opin HIV AIDS       Date:  2021-09-01       Impact factor: 4.061

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.